The online version of this article (https://doi.org/10.1007/s11523-017-0530-5) contains supplementary material, which is available to authorized users.
This phase I, four-arm, open-label study (NCT01347866) evaluated the PI3K/mTOR inhibitors PF-04691502 (arms A, B) and gedatolisib (PF-05212384; arms C, D) in combination with the MEK inhibitor PD-0325901 (arm A, D) or irinotecan (arm B, C) in patients with advanced solid tumors.
Primary endpoint was dose-limiting toxicity with each combination. Secondary endpoints included safety, pharmacokinetics and preliminary antitumor activity.
Dose escalation followed a 3 + 3 design in arm C and a zone-based design in arm D.
The PF-04691502 combination arms were closed prematurely due to low tolerability, and the maximum tolerated doses (MTDs) were not determined for either arm. The MTD for the combination of gedatolisib with irinotecan 180 mg/m2 was estimated to be 110 mg weekly and for the combination with PD-0325901 was not reached at the highest dose evaluated (gedatolisib 154 mg weekly). Plasma concentrations of gedatolisib were generally similar across dose groups in arm C (with irinotecan) and arm D (with PD-0325901). Frequent dose delays or dose reductions were required for both combinations, potentially preventing sustained therapeutic drug concentrations. Gedatolisib plus irinotecan produced a response rate of ~5% and clinical benefit in 16% of patients with advanced colorectal cancer (progression-free survival, 2.8 months). Preliminary evidence of clinical activity was observed with gedatolisib plus PD-0325901 in patients with ovarian cancer (three partial responses, n = 5) or endometrial cancer (one partial response, n = 1) and KRAS mutations.
Further evaluations of gedatolisib are warranted in patients with advanced solid malignancies.
ESM 1 (PDF 394 kb)11523_2017_530_MOESM1_ESM.pdf
Britten CD, Adjei AA, Millham R, et al. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer. Investig New Drugs. 2014;32(3):510–7. CrossRef
Wainberg ZA, Brega N, Davis C, et al. Randomized phase Ib/II study of PF-05212384 plus 5-fluorouracil-leucovorin-irinotecan (FOLFIRI) vs bevacizumab plus FOLFIRI in metastatic colorectal cancer (B2151007; NCT01937715). J Clin Oncol. 2014;32(15 suppl):TPS3657.
Tabernero J, Brega N, Davis C, et al. A randomized phase 2 study (B2151005) of PF-05212384 plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS metastatic colorectal cancer. J Clin Oncol. 2014;32(15 suppl):TPS3649.
Lim R, Sun Y, Im SA, et al. Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study. World J Gastroenterol. 2011;17(14):1879–88.
Grilley-Olson JE, Bedard PL, Fasolo A, et al. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. Investig New Drugs. 2016;34(6):740–9. CrossRef
Rodon J, Braña I, Siu LL, et al. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Investig New Drugs. 2014;32(4):670–81. CrossRef
LoRusso PM. Inhibition of the PI3K/AKT/mTOR pathway in solid tumors. J Clin Oncol. 2016;34(31):3803–15.
- A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
Zev A. Wainberg
Heloisa P. Soares
Carolyn D. Britten
Gianluca Del Conte
Kenneth A. Kern
Kristen J. Pierce
Lillian L. Siu
- Springer International Publishing
Neu im Fachgebiet Onkologie
Mail Icon II